This guidance suggested that the rigorous use of plaque‐stabilizing agents (statins, beta‐blockers, ACE inhibitors, acetylsalicylic acid) could offer additional protection to CVD patients during COVID‐19 epidemic.27 This evidence concerns the gene ACE and COVID-19.